London‑based NEX Health Intelligence has raised €1 million in pre‑seed funding to help hospitals get ahead of drug‑resistant infections before they spread further. The round was led by Brighteye Ventures and included participation from AFI Ventures, Adeline Arts and Science, Momentous Ventures, and the Conception X Angel Syndicate.

The startup is focused on a problem that remains stubbornly difficult in healthcare: identifying where an infection is likely to move next inside a hospital. Instead of relying purely on manual tracking or retrospective reporting, NEX wants to use predictive AI to map infection risk earlier and help clinicians respond before clusters become outbreaks.

Hospital‑acquired infections are expensive, disruptive, and often preventable. When a resistant pathogen moves through a ward, the consequences can stretch far beyond one patient, creating added pressure on staff, longer admissions, and higher treatment costs. NEX is positioning its technology as a decision‑support layer that gives infection control teams better visibility into those risks.

The company’s approach fits into a broader shift in healthtech toward predictive infrastructure. Rather than simply recording incidents after they happen, modern systems are increasingly expected to identify patterns, forecast escalation, and support faster intervention. That is especially relevant in hospitals, where timing can determine whether a risk is contained or becomes widespread.

NEX Health Intelligence says its platform is designed to help teams understand where transmission is most likely to happen next and act accordingly. That could mean more targeted cleaning, closer monitoring of specific wards, or quicker operational changes in areas with elevated exposure risk. In practice, the goal is to make infection prevention more proactive and less reactive.

The funding will also support regulatory work in the UK, a necessary step for any healthtech company hoping to move from early product development into real hospital environments. Healthcare buyers tend to be cautious, and with good reason: any AI system used in a clinical setting has to prove that it is safe, reliable, and genuinely useful in day‑to‑day operations.

Brighteye Ventures’ investment suggests growing confidence in AI products that solve narrow but important workflow problems inside healthcare systems. Those are often the tools that can gain traction fastest because they address clear operational pain points rather than abstract innovation goals.

NEX is still early, but its premise is compelling. Hospitals have long needed better ways to anticipate infection spread, especially as antimicrobial resistance remains a major global challenge. If the company can validate its model in the field, it could become a useful piece of the infection‑prevention toolkit.